Biotech - Rare Diseases
•215 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (215)
%
| Company | Market Cap | Price |
|---|---|---|
|
Rare diseases-focused biotech initiatives in the pipeline.
|
$11.75M |
$1.29
-4.30%
|
|
Strategic in-licensing of assets in oncology and rare diseases as part of pipeline expansion.
|
$9.38M |
$3.91
-5.10%
|
|
KALA's focus on rare ocular diseases (PCED and potential LSCD/Sjogren's ocular indications) places it in Biotech - Rare Diseases.
|
$9.23M |
$1.43
-7.74%
|
|
Adrulipase targets exocrine pancreatic insufficiency (EPI), a rare disease indication, placing Entero Therapeutics in Biotech - Rare Diseases.
|
$8.32M |
$5.24
+11.25%
|
|
Pipeline addresses orphan/rare retinal degenerative diseases, fitting Biotech - Rare Diseases.
|
$8.22M |
$2.70
-4.26%
|
|
MC-1 for PNPO deficiency targets a rare pediatric disease, aligning with the Rare Diseases biotech theme.
|
$7.83M |
$0.75
|
|
NF1 involvement places Pasithea in the realm of Rare Diseases through its NF1 trial program.
|
$5.58M |
$0.75
-3.55%
|
|
Dusquetide (IDR) programs (e.g., SGX945 for Behçet's Disease) target rare diseases, aligning with Biotech - Rare Diseases.
|
$5.48M |
$1.68
-5.08%
|
|
PCS499 is a non-oncology asset being re-evaluated for rare primary glomerular diseases, placing Rare Diseases within the pipeline.
|
$2.53M |
$0.21
+10.59%
|
|
Pipeline targets rare intestinal diseases (MVID, SBS-IF) and orphan indications, with regulatory catalyst opportunities (EMA PRIME, FDA Breakthrough) and potential non-dilutive funding.
|
$2.11M |
$2.07
-5.91%
|
|
The company is a late-stage biotech focused on rare/orphan diseases with its lead NS program, QRX003, aligning with Biotech - Rare Diseases.
|
$1.82M |
$7.20
-1.44%
|
|
Biotech - Rare Diseases: Type 1 diabetes cell therapy program expands into a rare disease indication via Kadimastem collaboration.
|
$1.73M |
$1.76
-4.35%
|
|
LP-410 has Orphan Drug Designation and targets a rare disease area (GVHD), indicating Lipella’s engagement in Rare Diseases.
|
$1.63M |
$0.64
+16.28%
|
|
VAR 200 and its renal disease indications (e.g., FSGS/DKD) align with Rare Diseases as a target space.
|
$350558 |
$0.14
-2.50%
|
|
Emmaus Life Sciences operates in the rare diseases space with Endari targeting sickle cell disease, aligning with the Biotech - Rare Diseases category.
|
$20252 |
$0.01
-3.83%
|
Showing page 3 of 3 (215 total stocks)
Loading industry metrics...
Loading comparison data...
